Inside This Issue: Spinal Cord Injury
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: NIH Corner
Company Spotlight: Sygnis
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Companies Dip Toes in IPO Waters, New Drugs Get Shaken Out
Three IPO filings were announced this month by companies with neuropharmaceuticals in development. BioLineRx, already listed on the TASE, filed for a $40 million IPO on NASDAQ. RNAi company Quark Pharmaceuticals is taking a shot at a $20 million IPO on the TASE after pulling a much larger offering on NASDAQ in 2007 (see stories, page 14). Zogenix is working towards an offering on NASDAQ after pulling their original offering in 2008 (see story, page 11). Regulatory panels quashed the prospects of novel drugs under consideration for approval in multiple sclerosis and obesity...
Who Will Step up to the Spinal Cord Injury Challenge?
Spinal cord injuries (SCI) often lead to devastating paralysis, muscle wasting and spasticity, loss of sensory awareness in the lower part of the body, and autonomous nervous system dysfunction. No restorative therapies exist as yet, although this is an area of intense activity and research. Therapeutic interventions with curative intent fall largely into two categories: cellular therapies that attempt to bridge cysts or cavities, replace dead cells, and create a favorable environment for axon regeneration; and molecular therapies that focus on neural protection, reversal of inhibitory scar products, promotion of axonal growth and enhancing nerve conduction. Additionally neurostimulation devices can be used to promote plasticity and supplement functioning in SCI patients... This article outlines spinal cord injury, current treatments and drug, cell and device therapies in development ...
Sygnis: Will Persistence Prevail in Stroke and Spinal Cord Injury
Sygnis Pharma is based in Heidelberg, Germany. The company has a complex history that started when former bioinformatics high-flyer LION Bioscience took over Axaron Bioscience through the acquisition of SYGNIS Bioscience in early 2006. The Hopp family, founders of SAP, had earlier acquired all shares of Axaron Bioscience AG through two of its subsidiaries, SYGNIS Bioscience and BASF AG. Axaron Bioscience, founded in 1997, was developing therapies for neurodegenerative diseases and its lead compound AX200, was in a Phase IIa clinical trial for stroke.. .
Companies Covered In This Issue Include: Rexhn, Zarlink, Progenics, Questcor, Neurogenic Pharma, Somaxon, Proctor & Gamble, Arcion, Abbott, Arena, Medtronic, Alkermes, Eisai, Neuronix, Orexigen, ImThera, Vivus, Catalyst, Titan, Takeda, Remynd, Second Sight Medical, Protagen, iPierian, Biogen Idec, Roche, Knopp Neuroscience, Zogenix, Rhythm, Orasi Medical, Zalicus, Acceleron, Shire, Eli Lilly, Neurocrine, Seaside Therapeutics, Icagen, Noscira, Archimedes, Actavis, Reckitt Benckiser, Hi-Tech Pharmacal, NeuroSigma, Geron, NeuroMetrix, BioAxone, Novartis, DaVinci, Q Therapeutics, Proneuron, NeuralStem, ReNeuron, California Stem Cell, RhinoCyte, Neurolink, Enteromedics, Cypress Bioscience, InControl Medical, Microtransponder, Pfizer, FoldRx, Phagenesis, Mind Research Network, BioLineRx, Quark, Xanodyne, Titan, NeurAxon, Biotectix, QR Pharma, Semprus, Remedy Pharma, RXi Pharma, EyeGate Pharma, MiRagen
Subscribe Now:
|
|
